JP2024521578A5 - - Google Patents
Info
- Publication number
- JP2024521578A5 JP2024521578A5 JP2023575588A JP2023575588A JP2024521578A5 JP 2024521578 A5 JP2024521578 A5 JP 2024521578A5 JP 2023575588 A JP2023575588 A JP 2023575588A JP 2023575588 A JP2023575588 A JP 2023575588A JP 2024521578 A5 JP2024521578 A5 JP 2024521578A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- pharmaceutical composition
- mixture
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208631P | 2021-06-09 | 2021-06-09 | |
| US63/208,631 | 2021-06-09 | ||
| PCT/US2022/032780 WO2022261284A1 (en) | 2021-06-09 | 2022-06-09 | Crystalline abdnaz compositions and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521578A JP2024521578A (ja) | 2024-06-03 |
| JP2024521578A5 true JP2024521578A5 (https=) | 2025-06-17 |
Family
ID=84425536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575588A Pending JP2024521578A (ja) | 2021-06-09 | 2022-06-09 | 結晶性ａｂｄｎａｚ組成物ならびにその作製方法及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240293360A1 (https=) |
| EP (1) | EP4351567A4 (https=) |
| JP (1) | JP2024521578A (https=) |
| KR (1) | KR20240019798A (https=) |
| CN (1) | CN117835979A (https=) |
| AU (1) | AU2022289720A1 (https=) |
| BR (1) | BR112023025535A2 (https=) |
| CA (1) | CA3221351A1 (https=) |
| IL (1) | IL309043A (https=) |
| MX (1) | MX2023014676A (https=) |
| TW (1) | TW202313001A (https=) |
| WO (1) | WO2022261284A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069420A (zh) | 2016-01-11 | 2018-12-21 | 埃皮辛特瑞柯斯公司 | 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 |
| US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
| WO2023178283A1 (en) * | 2022-03-18 | 2023-09-21 | Epicentrx, Inc. | Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507842B2 (en) * | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US8471041B2 (en) | 2010-02-09 | 2013-06-25 | Alliant Techsystems Inc. | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
| CN109069420A (zh) | 2016-01-11 | 2018-12-21 | 埃皮辛特瑞柯斯公司 | 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 |
| US11510901B2 (en) * | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
-
2022
- 2022-06-09 IL IL309043A patent/IL309043A/en unknown
- 2022-06-09 EP EP22821006.8A patent/EP4351567A4/en active Pending
- 2022-06-09 BR BR112023025535A patent/BR112023025535A2/pt unknown
- 2022-06-09 CA CA3221351A patent/CA3221351A1/en active Pending
- 2022-06-09 AU AU2022289720A patent/AU2022289720A1/en active Pending
- 2022-06-09 MX MX2023014676A patent/MX2023014676A/es unknown
- 2022-06-09 JP JP2023575588A patent/JP2024521578A/ja active Pending
- 2022-06-09 CN CN202280054886.0A patent/CN117835979A/zh active Pending
- 2022-06-09 US US18/568,625 patent/US20240293360A1/en active Pending
- 2022-06-09 WO PCT/US2022/032780 patent/WO2022261284A1/en not_active Ceased
- 2022-06-09 TW TW111121521A patent/TW202313001A/zh unknown
- 2022-06-09 KR KR1020247000307A patent/KR20240019798A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521578A5 (https=) | ||
| CN107087409B (zh) | 苯并杂环化合物及其应用 | |
| JP2023505756A5 (https=) | ||
| JP2023526451A5 (https=) | ||
| JP2022544280A5 (https=) | ||
| JP2024543505A5 (https=) | ||
| JP2023546009A5 (https=) | ||
| JP6878431B2 (ja) | がんに対するメルフルフェン投薬計画 | |
| IL263121A (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| CN111558044A (zh) | 一种包含舒尼替尼的药物组合物及其制剂和应用 | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| US20170066795A1 (en) | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv | |
| KR20180100614A (ko) | 식도암을 치료하기 위한 퀴놀린 유도체의 용도 및 치료방법, 이의 약제학적 조성물 및 키트 | |
| JP2013504590A5 (https=) | ||
| JP2024509265A5 (https=) | ||
| JP7631319B2 (ja) | 治療方法 | |
| TWI664174B (zh) | 雜環化合物及其用途 | |
| JP2021107447A5 (https=) | ||
| EP4319760A1 (en) | Ceftibuten dosing regimens | |
| JP2010215662A (ja) | １３−デオキシアントラサイクリン誘導体及びその製造方法 | |
| CN115779094A (zh) | 癌症联合治疗的组合物与方法 | |
| WO2024230772A1 (zh) | 包含抗her2双特异性抗体的联合治疗药物及其用途 | |
| Fujitani et al. | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer | |
| TW202120085A (zh) | 抗ccr4抗體抵抗性之癌症的治療劑 | |
| EP4714448A1 (en) | Use of trifluoromethyl-containing compound in treatment of hematological tumors |